跳至主要内容
临床试验/NCT05146336
NCT05146336招募中不适用

CytOSorb TreatMent Of Critically Ill PatientS Registry: International Registry on the Use of CytoSorb in the Critical Care Setting

CytoSorbents, Inc28 个研究点 分布在 6 个国家目标入组 3,000 人开始时间: 2022年6月22日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
3,000
试验地点
28
主要终点
In-hospital mortality

研究概览

简要总结

Registry intended to provide a data repository and reporting infrastructure for the surveillance of CytoSorb device use in real-world critical care settings, and to serve as an objective, comprehensive, and scientifically-based resource to measure and improve the quality of patient care

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Planned OR actual CytoSorb® 300 mL device utilization
  • Informed consent for prospective registry participation

排除标准

  • Use of the CytoSorb® 300 mL device for antithrombotic removal only
  • Intraoperative use of CytoSorb® 300 mL device during cardiac surgery only
  • The occurrence of a complication or other medically justified circumstance that arises after written informed consent has been obtained from the patient and before or during the planned therapy and as a result of which the use of CytoSorb® 300 mL Adsorber is contraindicated or no longer appropriate.

结局指标

主要结局

In-hospital mortality

时间窗: Through hospital discharge or date of death, whichever comes first [on average 14 days]

ICU mortality

时间窗: Through ICU discharge or date of death, whichever comes first [on average 7 days]

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (28)

Loading locations...

相似试验